GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (SHSE:688185) » Definitions » Net Interest Income

CanSino Biologics (SHSE:688185) Net Interest Income : ¥64.9 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is CanSino Biologics Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. CanSino Biologics's net interest income for the three months ended in Mar. 2024 was ¥23.4 Mil. Its net interest income for the trailing twelve months (TTM) ended in Mar. 2024 was ¥64.9 Mil.

CanSino Biologics Net Interest Income Historical Data

The historical data trend for CanSino Biologics's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Net Interest Income Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Interest Income
Get a 7-Day Free Trial 21.75 31.58 58.96 24.10 35.71

CanSino Biologics Quarterly Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.81 28.09 6.96 6.47 23.38

CanSino Biologics Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥64.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CanSino Biologics Net Interest Income Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

CanSino Biologics (SHSE:688185) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (SHSE:688185) » Definitions » Net Interest Income
Comparable Companies
HKSE:02005 HKSE:03933 HKSE:00512 HKSE:03613 HKSE:01349 HKSE:02096 HKSE:01558 HKSE:00570 HKSE:06600 HKSE:00460 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
CASBF:USA 06185:Hong Kong CJH:Germany
Address
185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
Website
https://www.cansinotech.com
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing and commercialization of vaccine products for human use. These include products such as pneumococcal polysaccharide and conjugate vaccines as well as a DTcP-based combo and other items. At the same time, the group is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine. Geographically, the activities are carried out through China.

CanSino Biologics (SHSE:688185) Headlines

No Headlines